These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 16253121)

  • 21. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an 'American lineage' H3N8 virus.
    Crouch CF; Daly J; Hannant D; Wilkins J; Francis MJ
    Vaccine; 2004 Dec; 23(3):418-25. PubMed ID: 15530689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
    Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
    Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of a whole inactivated EI vaccine against a recent EIV outbreak isolate and comparative detection of virus shedding.
    Paillot R; Prowse L; Donald C; Medcalf E; Montesso F; Bryant N; Watson J; Jeggo M; Elton D; Newton R; Trail P; Barnes H
    Vet Immunol Immunopathol; 2010 Aug; 136(3-4):272-83. PubMed ID: 20400185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
    Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM
    Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of trivalent inactivated influenza vaccines in the cotton rat Sigmodon hispidus model.
    Yim K; Miles B; Zinsou R; Prince G; Boukhvalova M
    Vaccine; 2012 Feb; 30(7):1291-6. PubMed ID: 22210139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms.
    Chen CY; Liu HJ; Tsai CP; Chung CY; Shih YS; Chang PC; Chiu YT; Hu YC
    Vaccine; 2010 Nov; 28(48):7644-51. PubMed ID: 20883735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.
    Lambkin R; Oxford JS; Bossuyt S; Mann A; Metcalfe IC; Herzog C; Viret JF; Glück R
    Vaccine; 2004 Oct; 22(31-32):4390-6. PubMed ID: 15474733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing.
    Noble S; McLain L; Dimmock NJ
    Vaccine; 2004 Aug; 22(23-24):3018-25. PubMed ID: 15297051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
    Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
    Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge.
    Deshpande MS; Jirjis FF; Tubbs AL; Jayappa H; Sweeney D; Spencer SJ; Lakshmanan N; Wasmoen TL
    Vet Ther; 2009; 10(3):103-12. PubMed ID: 20037964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
    Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
    Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses.
    Crouch CF; Daly J; Henley W; Hannant D; Wilkins J; Francis MJ
    Vet Immunol Immunopathol; 2005 Dec; 108(3-4):345-55. PubMed ID: 16098611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza.
    Huber VC; McKeon RM; Brackin MN; Miller LA; Keating R; Brown SA; Makarova N; Perez DR; Macdonald GH; McCullers JA
    Clin Vaccine Immunol; 2006 Sep; 13(9):981-90. PubMed ID: 16960108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine.
    Vincent AL; Lager KM; Janke BH; Gramer MR; Richt JA
    Vet Microbiol; 2008 Jan; 126(4):310-23. PubMed ID: 17719188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyper-reactivity in mice.
    Minne A; Jaworska J; Gerhold K; Ahrens B; Avagyan A; Vanbever R; Matricardi PM; Schmidt AC; Hamelmann E
    Clin Exp Allergy; 2007 Aug; 37(8):1250-8. PubMed ID: 17651156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.